UTSA researchers discover new pathways in brain’s amygdala

Click here to view original web page at www.utsa.edu

A rendering of the human brain highlighting the amygdala. The researchers, Alfonso Apicella, an associate professor in the Department of Biology, research associate Alice Bertero, postdoctoral fellow Paul Luc Caroline Feyen, and graduate student Hector Zurita, published their study, “A non-canonical cortico-amygdala inhibitory loop,” in The Journal of Neuroscience, […]

Diabetes drug relieves nicotine withdrawal

Click here to view original web page at www.eurekalert.org

IMAGE: PPARγ transcription levels in the central amygdala. view more Credit: Domi et al., JNeurosci 2019 A drug commonly used to treat Type II diabetes abolishes the characteristic signs of nicotine withdrawal in rats and mice, according to new research published in JNeurosci . The finding may offer an […]

Amygdala Neurosciences Awarded $1.35 million NIH Grant to Conduct Long Term, Phase 3 Enabling, Toxicology Studies

Click here to view original web page at www.prnewswire.com

SAN FRANCISCO, Oct. 21, 2019 /PRNewswire/ — Amygdala Neurosciences (a private company) has been awarded up to $1.35 million NIH grant support for the project titled “26- & 39-Week Toxicity Studies of ANS-6637 in Rats and Monkeys (respectively) to Enable 6+ Months Dosing in Alcohol (and other Substance) Use […]

Amygdala Neurosciences Announces Dosing of the First Patient in the NIH Funded Phase 2 Proof-Of-Concept study of ANS-6637 for the Treatment of Alcohol Use Disorder

Click here to view original web page at www.prnewswire.com

SAN FRANCISCO, Oct. 17, 2019 /PRNewswire/ — Amygdala Neurosciences (a private company) announced today the start of dosing in the National Institute on Alcohol Abuse and Alcoholism (NIAAA, an Institute of the National Institutes of Health (NIH)) sponsored Phase 2 proof-of-concept study of ANS-6637 in patients with alcohol use […]